Welcome to our dedicated page for TNL Mediagene Warrant SEC filings (Ticker: TNMWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TNL Mediagene filings document foreign private issuer current reports furnished on Form 6-K. The records cover board and executive-management changes, Nasdaq Capital Market listing compliance under the bid price rule, and exhibits such as press releases and shareholder letters.
The company's filings also disclose ordinary-share capital structure matters, including amendments to an equity line of credit purchase agreement, along with governance responsibilities, corporate development functions, investor relations, and research and development oversight for AI and strategic technology products.
TNL Mediagene reports that Nasdaq staff has determined its securities are subject to delisting from The Nasdaq Capital Market. Nasdaq cited two key issues: the company’s ordinary share closing bid price stayed below $1.00 for 30 consecutive business days from May 7, 2026 through June 18, 2026, and previously disclosed non-compliance with the $2,500,000 minimum stockholders’ equity requirement.
Because TNL Mediagene completed a reverse stock split within the prior year, it is not eligible for an additional compliance period under Listing Rule 5810(c)(3)(A)(iv). The company is already under a one-year Discretionary Panel Monitor and now plans to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay any suspension and Form 25-NSE filing. Its shares will continue trading under “TNMG” while the appeal is pending, but there is no assurance the company will regain compliance or maintain its Nasdaq listing.
TNL Mediagene reports that Nasdaq staff has determined its securities are subject to delisting from The Nasdaq Capital Market. Nasdaq cited two key issues: the company’s ordinary share closing bid price stayed below $1.00 for 30 consecutive business days from May 7, 2026 through June 18, 2026, and previously disclosed non-compliance with the $2,500,000 minimum stockholders’ equity requirement.
Because TNL Mediagene completed a reverse stock split within the prior year, it is not eligible for an additional compliance period under Listing Rule 5810(c)(3)(A)(iv). The company is already under a one-year Discretionary Panel Monitor and now plans to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay any suspension and Form 25-NSE filing. Its shares will continue trading under “TNMG” while the appeal is pending, but there is no assurance the company will regain compliance or maintain its Nasdaq listing.
TNL Mediagene reported that Nasdaq has notified the company it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company’s Form 20-F for the period ended December 31, 2025 showed stockholders’ equity of $918,088, below this threshold.
Nasdaq also determined the company does not meet the alternative standards based on market value of listed securities or net income from continuing operations. TNL Mediagene has until June 22, 2026 to submit a compliance plan and may receive up to 180 calendar days from the May 6, 2026 deficiency letter to regain compliance if its plan is accepted. Management is evaluating options and intends to submit the plan while the company’s shares remain listed during this process.
TNL Mediagene reported that Nasdaq has notified the company it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company’s Form 20-F for the period ended December 31, 2025 showed stockholders’ equity of $918,088, below this threshold.
Nasdaq also determined the company does not meet the alternative standards based on market value of listed securities or net income from continuing operations. TNL Mediagene has until June 22, 2026 to submit a compliance plan and may receive up to 180 calendar days from the May 6, 2026 deficiency letter to regain compliance if its plan is accepted. Management is evaluating options and intends to submit the plan while the company’s shares remain listed during this process.
TNL Mediagene reported FY2025 revenue of $45.0 million, below the preliminary outlook of $49.1 million, mainly due to softer performance and project delays in its digital studio and digital media businesses and consolidation adjustments.
The digital studio segment remained the core focus and largest unit, generating $18.7 million, or 41.4% of total revenue, supported by long-term clients in Japan and public-sector contracts in Taiwan. The company is integrating AI into content production and launched AI-assisted products in its digital studio business in late 2025.
Net loss narrowed significantly to $44.6 million in FY2025 from $85.0 million in FY2024, helped by the absence of a prior-year $38.2 million non-cash listing expense, lower professional fees and finance costs. However, results included a large $39.2 million non-cash impairment of goodwill and intangibles tied to its Japan Mediagene business after projections were revised downward.
The company’s liquidity is tight, with $1.9 million in cash and cash equivalents at December 31, 2025, and its audited financials carry a going concern emphasis, stating it needs additional financing to fund operations beyond FY2026. Management drew on an equity line of credit, issued equity and convertible debt, and is exploring further funding options.
TNL Mediagene also disclosed that internal control over financial reporting was not effective as of year-end due to three material weaknesses still under remediation. A leadership realignment and FY2026 strategic initiatives aim to sharpen focus on digital studio services, content commerce and AI-powered products alongside ongoing cost efficiency measures.
TNL Mediagene reported FY2025 revenue of $45.0 million, below the preliminary outlook of $49.1 million, mainly due to softer performance and project delays in its digital studio and digital media businesses and consolidation adjustments.
The digital studio segment remained the core focus and largest unit, generating $18.7 million, or 41.4% of total revenue, supported by long-term clients in Japan and public-sector contracts in Taiwan. The company is integrating AI into content production and launched AI-assisted products in its digital studio business in late 2025.
Net loss narrowed significantly to $44.6 million in FY2025 from $85.0 million in FY2024, helped by the absence of a prior-year $38.2 million non-cash listing expense, lower professional fees and finance costs. However, results included a large $39.2 million non-cash impairment of goodwill and intangibles tied to its Japan Mediagene business after projections were revised downward.
The company’s liquidity is tight, with $1.9 million in cash and cash equivalents at December 31, 2025, and its audited financials carry a going concern emphasis, stating it needs additional financing to fund operations beyond FY2026. Management drew on an equity line of credit, issued equity and convertible debt, and is exploring further funding options.
TNL Mediagene also disclosed that internal control over financial reporting was not effective as of year-end due to three material weaknesses still under remediation. A leadership realignment and FY2026 strategic initiatives aim to sharpen focus on digital studio services, content commerce and AI-powered products alongside ongoing cost efficiency measures.
TNL Mediagene files its annual Form 20-F, highlighting severe financial stress and a going concern warning. For the year ended December 31, 2025 it recorded a loss from operations of approximately $49.6 million, operating cash outflow of $4.9 million, negative working capital of $17.5 million and an accumulated deficit of $161.8 million.
The company relies on equity and debt financings, raising $1.9 million via Tumim ELOC shares, $2.2 million via PIPE shares and issuing a $1.5 million Second Note in 2025, alongside about $3.9 million in loan facilities. It also recognized a $39.2 million impairment on intangibles, including fully writing off $25.5 million of Mediagene goodwill, while carrying remaining intangibles of $24.3 million and goodwill of $8.7 million as of December 31, 2025.
The report underscores heavy dependence on digital advertising in Japan and Taiwan, traffic from platforms such as Google, and exposure to structural shifts from AI-driven search and content discovery. It also details significant technology, data privacy, AI, third-party license, and infrastructure risks. As of December 31, 2025, there were 2,556,405 ordinary shares outstanding following a 1‑for‑20 reverse share split in December 2025.
TNL Mediagene files its annual Form 20-F, highlighting severe financial stress and a going concern warning. For the year ended December 31, 2025 it recorded a loss from operations of approximately $49.6 million, operating cash outflow of $4.9 million, negative working capital of $17.5 million and an accumulated deficit of $161.8 million.
The company relies on equity and debt financings, raising $1.9 million via Tumim ELOC shares, $2.2 million via PIPE shares and issuing a $1.5 million Second Note in 2025, alongside about $3.9 million in loan facilities. It also recognized a $39.2 million impairment on intangibles, including fully writing off $25.5 million of Mediagene goodwill, while carrying remaining intangibles of $24.3 million and goodwill of $8.7 million as of December 31, 2025.
The report underscores heavy dependence on digital advertising in Japan and Taiwan, traffic from platforms such as Google, and exposure to structural shifts from AI-driven search and content discovery. It also details significant technology, data privacy, AI, third-party license, and infrastructure risks. As of December 31, 2025, there were 2,556,405 ordinary shares outstanding following a 1‑for‑20 reverse share split in December 2025.
TNL Mediagene announced a leadership realignment and 2026 strategic plan focused on execution, AI and higher-margin services. Motoko Imada becomes Chief Executive Officer, retaining her Chief Operating Officer role and taking full control of operations, P&L, budgets and a company-wide business and cost review. Former CEO Joey Chung becomes President, leading corporate development, strategic transactions, partnerships, capital markets work and investor relations. CTO Richard Lee now also heads Research and Development to build and commercialize AI and strategic technology products, while General Counsel TJ Park is promoted to Chief Corporate Affairs Officer. Co‑founder Hiroto Kobayashi joins the Board, filling a vacancy. For 2026, the company targets organic revenue growth, positive EBITDA, lower SG&A as a share of revenue, an accelerated pivot toward digital studio services, content commerce and AI-powered products, and a portfolio review that may lead to divestitures, downsizing or closure of underperforming media brands.
TNL Mediagene announced a leadership realignment and 2026 strategic plan focused on execution, AI and higher-margin services. Motoko Imada becomes Chief Executive Officer, retaining her Chief Operating Officer role and taking full control of operations, P&L, budgets and a company-wide business and cost review. Former CEO Joey Chung becomes President, leading corporate development, strategic transactions, partnerships, capital markets work and investor relations. CTO Richard Lee now also heads Research and Development to build and commercialize AI and strategic technology products, while General Counsel TJ Park is promoted to Chief Corporate Affairs Officer. Co‑founder Hiroto Kobayashi joins the Board, filling a vacancy. For 2026, the company targets organic revenue growth, positive EBITDA, lower SG&A as a share of revenue, an accelerated pivot toward digital studio services, content commerce and AI-powered products, and a portfolio review that may lead to divestitures, downsizing or closure of underperforming media brands.
TNL MEDIAGENE disclosed that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC beneficially own 171,113 ordinary shares, representing 6.3% of the company’s ordinary share class as of the event date.
The Goldman Sachs entities report shared voting and dispositive power over all 171,113 shares and no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of TNL MEDIAGENE.
TNL MEDIAGENE disclosed that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC beneficially own 171,113 ordinary shares, representing 6.3% of the company’s ordinary share class as of the event date.
The Goldman Sachs entities report shared voting and dispositive power over all 171,113 shares and no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of TNL MEDIAGENE.
TNL Mediagene has regained compliance with Nasdaq’s minimum bid price requirement, allowing its shares to remain listed on the Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) after the closing bid price of its ordinary shares stayed at $1.00 per share or higher for fifteen consecutive trading days from December 23, 2025 to January 14, 2026.
At the same time, Nasdaq’s Hearings Panel imposed a one-year Discretionary Panel Monitor starting January 20, 2026. During this period, if the company fails any continued listing standard, it will not receive extra time or a cure period; instead, Nasdaq staff will issue a delisting determination, though the company may request a new hearing.
TNL Mediagene has regained compliance with Nasdaq’s minimum bid price requirement, allowing its shares to remain listed on the Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) after the closing bid price of its ordinary shares stayed at $1.00 per share or higher for fifteen consecutive trading days from December 23, 2025 to January 14, 2026.
At the same time, Nasdaq’s Hearings Panel imposed a one-year Discretionary Panel Monitor starting January 20, 2026. During this period, if the company fails any continued listing standard, it will not receive extra time or a cure period; instead, Nasdaq staff will issue a delisting determination, though the company may request a new hearing.
TNL Mediagene filed an amended Form 6-K to update a previously furnished report. The amendment applies only to Exhibit 99.1, which is an amended press release dated September 17, 2025. The company states this change is solely to remove references to certain company names and that no other changes have been made to the original report.
TNL Mediagene filed a Form 6-K describing a third amendment to its equity line of credit ordinary share purchase agreement with Tumim Stone Capital LLC, originally dated November 25, 2024. The amendment, signed on September 14, 2025, changes how Tumim’s purchases of TNL Mediagene ordinary shares are valued.
The company can now choose to have its ordinary shares priced over either a one-trading-day or a three-trading-day valuation period, based on the market price and/or trading volume of the shares. The amendment also makes related changes to the maximum purchase amount and purchase price Tumim will use when buying shares under the equity line arrangement.